Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium animalis ssp. lactis 420 + polydextrose
- Development stage
- Unknown
- Lead developer
- DuPont Nutrition Biosciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis ssp. lactis 420 + polydextrose is a synbiotic combination consisting of the probiotic strain Bifidobacterium animalis ssp. lactis 420 (B420) and the prebiotic fiber Litesse Ultra polydextrose (LU). Developed by IFF (formerly DuPont Nutrition & Health and Danisco), this combination is primarily investigated for weight management and the reduction of body fat mass in overweight and obese adults. The mechanism of action involves modulating the gut microbial community composition (e.g., increasing Akkermansia muciniphila), increasing the production of beneficial metabolites like short-chain fatty acids (propionate, butyrate), and improving gut barrier integrity, as evidenced by reduced levels of the permeability marker zonulin. Clinical data from a six-month randomized, double-blind, placebo-controlled trial (NCT01978691) demonstrated that the synbiotic significantly reduces total body fat mass, trunk fat, and waist circumference while also decreasing daily energy intake.
- Brand names
- HOWARU ShapeLitesse Ultra
- Other names
- B420 + LUBifidobacterium animalis ssp. lactis 420 + Litesse Ultra polydextrose
Beyond the preview
Go deeper on bifidobacterium animalis ssp. lactis 420 + polydextrose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium animalis ssp. lactis 420 + polydextrose.